Interferon lambdas: the next cytokine storm

Christabel Kelly, Paul Klenerman, Eleanor Barnes

ABSTRACT

For two decades the scientific community has sought to understand why some people clear hepatitis C virus (HCV) and others do not. Recently, several large genome-wide association studies have identified single nucleotide polymorphisms (SNPs) linked to interferon lambda 3 (IFNL3) that are associated with the spontaneous resolution and successful treatment of HCV infection. These observations are generating intense research activity; the hope is that IFNL3 genetic variants may serve as important predictive biomarkers of treatment outcome and offer new insights into the biological pathways involved in viral control. A pharmacogenomic treatment approach for HCV can now be envisaged, with the incorporation of host genetic variants into a predictive treatment algorithm with other factors. The SNPs associated with the clinical outcome of HCV infection are located some distance from the IFNL3 gene itself, and causal genetic variants have yet to be clearly defined. Locating these causal variants, mapping in detail the IFNL3 signalling pathways and determining the downstream genetic signature so induced will clarify the role of IFNL3 in the pathogenesis of HCV. Clinical studies assessing safety and efficacy in the treatment of HCV with exogenous IFNL3 are currently underway. Early results suggest that IFNL3 treatment inhibits HCV replication and is associated with a limited side effect profile. However, hepatotoxicity in both healthy volunteers and HCV-infected patients has been described. This review discusses the genetic studies that link IFNL3 to both the spontaneous resolution and treatment-induced clearance of HCV and the potential impact of this in clinical practice, the biology of IFNL3 as currently understood and how this may impact on HCV infection, and describes the early studies that assess the role of this cytokine in the treatment of patients with HCV.

INTRODUCTION

For more than two decades, interferon-α (IFNα) treatment has formed the cornerstone of therapy for hepatitis C virus (HCV) infection. Despite the identification of some viral and host factors associated with viral clearance, response to therapy remains highly unpredictable. Since treatment is prolonged, expensive and fraught with side effects, intense efforts have been made to identify biomarkers predictive of a successful treatment outcome. In 2009 there was a major breakthrough in this endeavour with the discovery that single nucleotide polymorphisms (SNPs) linked to the cytokine IFNL3 (also known as IL28B) are a dominant host factor at a population level in determining treatment outcome. Furthermore, the same SNPs are associated with the clinical outcome of primary infection—an intense area of research in the field of HCV over recent years. It is therefore not surprising that IFNL3 is creating a storm in the HCV arena.

This review describes the discovery of IFNL3-linked SNPs that are associated with HCV control, summarises the biology and function of IFNL3 as currently understood and describes the early studies that assess the role of this cytokine in the treatment of patients.

Identification of IFNL3 as a key cytokine in HCV infection using genetic technology

Over the last decade a number of host factors have been shown to play a role in the clinical outcome of HCV using either a candidate gene approach or through the assessment of biological pathways or demographic features that have an expected role in infection control. For example, in acute infection, particular human leucocyte antigens (both HLA classes I and II) and robust T cell immunity have been associated with viral clearance. Single-source HCV outbreak studies most clearly demonstrate the importance of host factors in response to HCV infection. In these studies, young women were infected with the same inoculum of HCV from contaminated anti-D immunoglobulin. Approximately half of the women developed persistent infection while the remainder cleared the virus spontaneously, showing that host factors are important in determining clinical outcome. Similarly, in the treatment of persistent HCV infection, some host factors such as male gender and African ethnicity are associated with a poor treatment outcome. However, the actual predictive value of these factors is low, suggesting that other factors, hitherto unidentified, must exist. These observations provided the rationale for fully assessing the contribution of the host genome to the outcome of HCV infection.

The development of the human HapMap project in 2002 and advances in genetic techniques that facilitate the analysis of large datasets has led to an exponential growth in genome-wide association studies (GWAS). These studies associate common SNPs throughout the host genome with a disease cohort, and so identify important biological pathways in disease without prior knowledge or prejudice as to their relevance. This technique contrasts with candidate gene studies that take a pre-identified relevant gene and specifically assess its prevalence in the target population. The polarised clinical
outcome of HCV infection (that of viral clearance versus viral persistence) makes HCV infection an ideal candidate for a GWAS approach.

The first GWAS in HCV infection was published by Ge and colleagues in September 2009. This study assessed the treatment outcome in a group of 1671 patients of mixed ethnicity (American European, Hispanic and African) receiving pegylated-IFN (PEG-IFN) and ribavirin. A striking association was discovered between sustained viral response (SVR) with treatment and a cluster of seven SNPs linked to the IL28B gene, with the most significant SNP (rs12979860) demonstrating extremely high statistical significance (p = 1.06 × 10^{-25}). No SNPs linked to other genes were associated with treatment outcome at genome-wide significance. Patients homozygous for the protective allele (C/C) had an SVR rate that was approximately three times higher than homozygotes for the risk allele (T/T) (78% vs 28%), and simply being a heterozygote carrier (T/C) for the risk allele also demonstrated approximately a twofold decrease in SVR (38%) compared with those homozygous for the protective allele, suggesting a dominant role for the risk SNP.

Many other studies have since replicated these findings, demonstrating the robust association between IFNλ and treatment outcome in other populations including Japanese, Australian, European, African American and Hispanic using either a GWAS approach or a candidate gene approach (table 1, figures 2 and 3).

Shortly after the landmark publication by Ge et al., the same gene (using a candidate gene approach assessing SNP 12979860) was shown to play a key role in the spontaneous resolution of disease following primary infection in both African and Caucasian populations. This study showed that carriers of the risk allele were three times less likely to spontaneously clear the virus than homozygotes for the protective allele. This finding was subsequently supported in a large GWAS by pushing the odds ratio (OR) of treatment failure in hepatitis C virus (HCV) infection. OR of risk factors associated with treatment failure including the interferon λ3 (IFNλ3)-linked single nucleotide polymorphisms (SNPs) linked to interferon λ3 (IFNλ3) associated with treatment response or spontaneous clearance.

| GWAS                     | SNP linked to IFNλ3 | Position in relation to IFNλ3, + (upstream), L (downstream) | Wild Type/ | Risk allele | Population studied | OR of spontaneous clearance | OR of treatment outcome (95% CI) | Viral genotype |
|--------------------------|--------------------|-------------------------------------------------------------|------------|-------------|--------------------|----------------------------|---------------------------------|---------------|
| Ge et al                 | rs12979860         | +3 kbp                                                       | C/T        | T            | European-American (30%) | NA                         | 7.3 (95% CI 5.10 to 10.4)*      | Europeans 7.3 (95% CI 1.3 to 15.9) |
|                          |                    |                                                              |            |              | Hispanic (40%)        | NA                         | 6.1 (95% CI 2.3 to 15.9)       | Hispanics 6.1 (95% CI 1.4 to 22.1) |
|                          |                    |                                                              |            |              | African-American (60%) | NA                         | 5.6 (95% CI 2.3 to 13.1)       | African-Americans 5.6 (95% CI 1.4 to 22.1) |
|                          |                    |                                                              |            |              | Japanese (15%)        | NA                         | 3.5 (95% CI 1.6 to 7.3)        | Japanese 3.5 (95% CI 1.1 to 11.6) |
|                          |                    |                                                              |            |              | Swiss (11%)           | NA                         | 2.6 (95% CI 1.1 to 5.9)        | Swiss 2.6 (95% CI 1.1 to 6.0) |
|                          |                    |                                                              |            |              | German (12%)          | NA                         | 1.9 (95% CI 1.0 to 3.6)        | German 1.9 (95% CI 1.0 to 3.6) |

*Derived from Rauch et al.

**Table 1**: Comparison of genome-wide association studies (GWAS) identifying single nucleotide polymorphisms (SNPs) linked to interferon λ3 (IFNλ3) associated with treatment response or spontaneous clearance.

---

Figure 1: Odds ratio (OR) of treatment failure in hepatitis C virus (HCV) infection. OR of risk factors associated with treatment failure including the interferon λ3 (IFNλ3)-linked single nucleotide polymorphisms (SNPs) linked to interferon λ3 (IFNλ3) in published genome-wide association studies. *Derived from Rauch et al.*
Rauch et al. in both HCV-infected patients and HIV and HCV co-infected patients. It is now quite clear that the IFNα pathway plays a key role in natural host immunity as well as in the response to IFNα treatment of HCV infection.

Although the SNPs identified in the first phase of the GWAS above are linked to the IFNα3 gene, they are not located within known regulatory elements or the coding region of the IFNα3 gene itself. Rather, they have an expected association with ‘functional’ polymorphisms involved in the regulation or the function of the IFNα3 gene product. This is because IFNα3 has a distinct haplotype block (distinct regions of the host genome with SNPs that are in tight linkage disequilibrium with one another) that extends beyond the gene and the gene regulatory elements. The most significantly associated SNP identified by Ge and colleagues (rs12979860) lies 3 kb upstream of the IFNα3 gene.8 In an attempt to identify the functional (or causal) polymorphism, these authors sequenced the IFNα3 gene itself in 96 individuals and found two variants (one 37 base pairs upstream of the translation initiation codon (rs28416813) and a non-synonymous coding SNP (rs8103142) encoding an amino acid substitution within the IFNα3 gene. However, these variants were so tightly linked that further genotyping of the entire cohort failed to show that any of these SNPs were uniquely linked to treatment outcome. Several studies have identified SNP rs8099917 as that most significantly associated with outcome.9-11 This SNP is located 8.9 kb from the end of transcription of IFNα3 in the intergenic region between IFNα2 and IFNα3. Suppiah and colleagues further clarified the association and genotyped 20 SNPs in the IFNα3, IFNα2, IFNα1 gene cluster region.10 Haplotype analysis identified a six-allele haplotype that was tagged by rs8099917 (rs12980273, rs8105790, rs8103142, rs10835727, rs8109886 and rs8099917) linked to SVR. Notably, this haplotype encompasses regulatory elements from both IFNα3 and IFNα2. Tanaka and colleagues also sequenced 48 patients and established a similar seven-allele haplotype (rs8105790, rs11881222, rs8103142, rs28416813, rs4805219, rs8099917 and rs7248668) associated with SVR (OR 11.1 (p=1.35×10-25, 95% CI 6.6 to 18.6).11 Similarly, Rauch and colleagues, in searching for the causal variants, resequenced the IL28B locus in 47 individuals with and without the SNP rs8099917 and with different treatment outcomes and identified 21 SNPs, of which five tightly linked SNPs were thought to be potentially causative.9

Since multiple tightly-linked SNPs within and around the IFNα3 gene are associated with SVR, it seems unlikely that sequence studies of the IFNα3 region in association with known clinical outcome will identify which of these are causal. In vitro IFNα3 functional assays combined with mutagenesis studies will determine the effect of these polymorphisms on IFNα3 function, although even these may not prove causality. A further note of caution: while it is generally assumed that common variants associated with disease in GWAS reflect the effect of a causal variant in close proximity, this is not necessarily so. Rare causal variants cannot be detected using GWAS technology, which only screens the human genome for common SNPs. An alternative possibility, therefore, is that multiple rare variants that lie distant from the common variant identified in GWAS occur stochastically and more frequently in association with the GWAS common variant. These associations have been termed ‘synthetic’.19 In this scenario a common variant identified in the GWAS will be erroneously linked to a disease due to its chance association with the true causal variants which lie undetected by GWAS methodology. This possibility has been demonstrated by the analysis of existing datasets.
Recent advances in basic science

showing that known rare causal mutations responsible for sickle cell disease and hearing loss can give rise to genome-wide significant synthetic associations that lie a considerable distance (2.5 Mb) from the causal mutations.20 These observations do not detract from the use of the GWAS variants in predicting treatment outcome in HCV infection, but they do raise the possibility that the biological mechanisms that underpin this are related to distant multiple rare genetic variants.

It has been known for some time that ethnicity affects treatment outcome of HCV infection, with viral clearance rates lowest in African-Americans, highest in East Asians and intermediate in European-Americans.5–7 We now know that the underlying rate of carriage of the IFNλ3 risk allele depends on the ethnic group of the population under study (figure 3). This suggests that ethnic differences in the IFNλ3 gene may explain, at least in part, the different response rates to therapy in different ethnic groups. Although one study did not find an association with IFNλ3 in the African-Americans studied, it is likely the group (n=53) was underpowered to identify the association.15

The data supporting a major role for the IFNλ3 gene in clinical outcome is less clear for genotypes 2 and 3 infection than for genotype 1. The largest study of 1562 patients by Rauch and colleagues9 and a smaller Spanish study14 found no association between genotypes 2 and 3 and IFNλ3 polymorphisms, although the treatment failure rate in both studies was very low (37/230 patients and 9/59 patients, respectively). In contrast, two other groups have found that IFNλ3 status can predict SVR in genotypes 2 and 3 infection, although in one of these studies the effect was restricted to patients who did not achieve a rapid virological response.13 15 Intriguingly, McCarthy and colleagues also showed that the protective IFNλ3 genotype is enriched in patients infected with genotype 3 HCV compared with genotype 1 (p=0.0007).15 The mechanism behind this observation is speculative but, since the protective allele is almost universal in Asian populations where genotype 3 infection has evolved,16 it seems plausible that this genotype may have evolved mechanisms to persist following acute infection in the face of the protective allele.

It remains to be seen how we can best use the information about IFNλ3 in clinical practice. In genotype 1 infection, IFNλ3 is the best predictor of treatment outcome when compared with other known baseline predictors including fibrosis score, viral load, gender and ethnicity.8 9 11 15 However, the sensitivity, specificity and predictive value of the IFNλ3 genetic variants currently identified are too low to be clinically useful alone. It has been calculated that the risk allele predicts non-response to treatment with a sensitivity of 57% and specificity of 63% with a positive predictive value of 64%.10 For homozygotes with the protective allele, SVR can be predicted with 65% sensitivity and 78% specificity in patients with genotype 1.15 It is plausible, however, that IFNλ3 allelic status will in future be incorporated into a treatment algorithm with other known predictors.

THE BIOLOGY OF INTERFERON LAMBDAS

The GWAS point to IFNλ as a key cytokine in the control of HCV infection. Is this biologically plausible? What do we know currently about the role and function of IFNλ?

Since their discovery in 2005,21 22 IFNλs (a type III IFN) have largely been considered a ‘poor relative’ of type I IFNs. Many functions appeared to overlap with type I IFNs and until now there has been little evidence of an independent and clinically significant role. Although the GWAS data suggest that IFNλ5 may be the type III IFN most relevant to the pathogenesis of HCV, historically the assessment of IFNλ biology has focused on IFNλ1 and IFNλ2.

Classification

IFNλs are classified within the class II cytokine family based on the similarity of their receptors. The class II family of cytokines consists of three types of IFNs (types I, II and III) as well as the interleukin 10 (IL-10)-related cytokines. Type I IFNs include IFNα and IFNβ, type II IFN is IFNγ and type III IFNs consist of IFNλ1, IFNλ2 and IFNλ3 which are also called IL29, IL28A and IL28B, respectively. IFNλ3 shares considerable amino acid sequence homology with IFNλ2 (96%) but less with IFNλ1 (81%).21 There are currently very limited available data comparing the different biological activity of the three different λ cytokines.

Although class II cytokines may be quite divergent at the amino acid level, they are structurally related with a shared α-helical pattern and signal through related heterodimeric transmembrane protein receptors. However, biological activity ultimately depends on the receptor cytoplasmic domains, which are not related, and these may trigger overlapping but different biological functions. This, in addition to the pattern of receptor distribution among different cell types, means that the different type II cytokines are functionally distinct.

Production of IFNλ

Broadly speaking, the IFNλ family is similar to IFNα in that it has both antiviral and immunomodulatory properties, but there are important differences. Whereas IFNα is produced by all nucleated cells, IFNλ may be produced by fewer cell types.23 Plasmacytoid monocyte-derived dendritic cells (pDC and MDDC) and macrophages produce IFNλ in response to influenza virus infection and/or to bacterial and viral molecular mimics (the Toll-like receptor agonists lipopolysaccharide and poly I:C).24 25 Interestingly, macrophage production of IFNλ is markedly enhanced by pre-culturing these cells with IFNα—evidence of interplay between the two pathways.26 27 There is evidence that IFNλ secretion may be influenced by cytokines—for example, pDCs produce an
**IFNλ3 and genetic technology**

- SNPs are single base pair mutations and are the main sites of genetic variation between individuals.
- SNPs linked to the IFNλ3 gene predict both treatment response to PEG-IFNα/ribavirin and spontaneous clearance of HCV.
- Individuals either heterozygous or homozygous for the risk allele are less likely to clear HCV infection than those homozygous for the protective allele.
- African populations have a higher frequency of the risk allele than Caucasian or East Asian populations.
- Carriers of the IFNλ3 risk allele are 2–12 times more likely to fail treatment than homozygotes for the protective allele.
- The predictive value of the IFNλ3 alleles alone is insufficient to determine treatment outcome but may be a useful component of a treatment algorithm in the future.

Increased amount of IFNλ in response to IL-4 through a monocyte intermediate pathway.\(^{23}\).

There is also evidence that IFNλ has a particular role in skin biology, being readily produced there by regulatory T cells and dendritic cells and acting upon keratinocytes and melanocytes.\(^{28}\) With particular relevance to HCV infection, hepatocyte tumour lines (HepG2 and HuH7.5).\(^{22,27}\) primary hepatocytes cultured ex vivo and liver tissue obtained from liver biopsy specimens produce IFNλ in response to viral infection.\(^{29}\) In contrast, primary human CNS tissue does not produce IFNλ.\(^{25}\)

### IFNλ receptor distribution and signalling

The IFNλ receptor also has a limited cellular distribution. IFNλs signal through a heterodimeric receptor composed of a short IL-10Rβ chain (also called IL-10R2) and a long chain IL-28Rα (also called IL-28R1).\(^{21,22,30}\) Whereas the short chain is ubiquitously expressed and is a receptor component of other type II-related cytokines (IL-10, IL-22, IL-26), the long chain is unique to IFNλ and has a limited tissue distribution.\(^{30}\)

Hepatocytes from liver biopsy specimens have a high IFNλ receptor expression (IL-28Rα).\(^{23,30,31}\) However, this receptor is not found on fibroblasts, microvascular endothelial cells, adipocytes\(^{30}\) or primary CNS cells.\(^{25,30}\)

It is likely that the limited receptor profile accounts for the relatively restricted side effect profile of IFNλ when administered to patients. Immune cells are an important target of IFNλ in general, however not all appear to express the IFNλ receptor. B cells have been shown to have the highest level of receptors, whereas the data on T cells are conflicting with both high and low receptor levels reported.\(^{30,31}\) Monocytes also appear to have a minimal receptor expression.\(^{30–32}\)

All class II cytokines signal through the signal transducers and activators of transcription (STATs) and janus tyrosine kinases (JAK) and the biological properties of all IFNs—especially type I IFNs and the IFNλs—clearly overlap. In particular, both are produced in response to viral infection and have antiviral properties. However, within this signalling cascade there are subtle differences between the IFNs that are not fully understood. All class II cytokines appear to activate STAT1 and STAT3 and bind to IFNγ-activated sites (GAS) to various extents in the cell nucleus, resulting in the transcription of IFN-stimulated genes (ISGs). However, in addition, type I IFNs and IFNλ also activate IFN-stimulated response elements (ISRE) through the activation of STAT2 in association with STAT1 and IRF9 and which again results in the production of IFN-stimulated genes (figure 4).\(^{33,34}\)

### Biological effects of IFNλ

Microarray experiments have shown that hundreds of ISGs are produced in response to IFN stimulation. The full spectrum of genes that are stimulated in response to different IFNs has not been defined, but it is clear that even different IFNs that bind to the same receptor may ultimately induce different genes,\(^{35,36}\) and that mutations in a single amino acid in key locations in the IFNλ binding site can have a significant impact on antiviral activity, altering antiviral activity by up to 300-fold.\(^{37}\)

Marcello et al evaluated ISG expression, protein production and HCV RNA replication using the HCV replicon system with cell culture HCV in response to IFNλ and IFNλ stimulation.\(^{38}\) Both cytokines ultimately inhibited HCV replication in this system. However, the kinetics of STAT activation and the potential effector genes induced differed. In particular, IFNλ genes peaked and declined rapidly whereas IFNλ genes increased steadily. Thus, the functional differences and the interplay between types I and III IFNs are likely to lie in the fine detail of this signalling pathway, yet to be fully elucidated for IFNλ, and in the differential distribution of cells that both produce IFNλ and are able to respond to IFNλ through the presence of appropriate receptors.

The effects of IFNλ, like that of IFNγ, on immune cell function appear to be complex and diverse. This means that in vitro studies of discrete functions, such as the in vitro effects of IFNλ on an isolated cell type, may tell us little about the in vivo effects in a particular disease setting where a complex interplay of cell types and inflammatory stimuli is at work. With that proviso, IFNλ has been shown to decrease the production of Th2-type cytokines (IL-4, IL-5, IL-13, IL-14, IL-15), potentially favouring a Th1 immune pathway,\(^{39–41}\) increase T regulatory cells\(^{32,42}\) and augment CD8 T cell cytotoxicity and memory responses in macaques vaccinated with an HIV antigen.\(^{42}\)

However, others have shown that immune cell subsets (monocytes, NK, T cells) are unresponsive to IFNλ1 and IFNλ2 and postulated that this is due to the production of a soluble receptor produced by peripheral blood mononuclear cells.\(^{30,32,43}\)

The antiviral effects of IFNλ are clearer; in vitro IFNλ protects human cell lines against the cytopathic effects of vesicular stomatitis virus (VSV) and encephalomyocarditis virus\(^{21,22}\) and, in hepatocyte models, IFNλ1 inhibits both HCV and HBV replication.\(^{31,38,44}\) However, some studies have shown that, unlike IFNγ, IFNλ1 is unable to suppress HCV completely\(^{38}\) and all groups found it was less...
potent than IFNα. The antiviral effects of IFNλ on HCV infection in patients have also been demonstrated and are discussed further below. In this case, however, it is unclear if the antiviral effects are mediated directly or through the stimulation of immune cells, or both. It should be remembered that, in the case of chronic HCV infection, the presumed effects of IFNα on viral clearance revealed in the GWAS are mediated through treatment with exogenous IFNα. How then might these cytokines interact with one another? Although IFNλ may be less potent than IFNα as a direct antiviral, together these cytokines may have an additive effect. In macrophages and hepatoma cell lines it has been shown that IFNα upregulates IFNλ1 production 1000-fold and IFNλ2/10-fold. 

Effect of IFNλ3 polymorphism on IFNλ biology

It is not yet clear how—or indeed if—IFNλ3 polymorphisms linked to the risk allele identified in the GWAS affect immune function or exert specific antiviral effects in HCV-infected patients. This will be a difficult task unless a causal IFNλ3 variant is identified, enabling the precise assessment of the relevant IFNλ3 variants in vitro. Currently, this assessment can only be made indirectly by observing immune function or HCV viral loads in people with and without the risk allele that lies a considerable distance from the IFNλ3 gene. It is currently not clear if IFNλ3 production by peripheral blood mononuclear cells (PBMCs) is associated with the IFNλ3-linked genetic variants; while two studies found that the protective allele is associated...
with increased levels of IFNλ3 in PBMCs, others have found it to be unrelated. However, a consistent finding appears to be that patients with the IFNλ3-linked protective allele have a higher pretreatment HCV viral load than those with the risk allele, with Ge and colleagues finding that those homozygous for the protective allele had a viral load of 6.35log_{10} 1U/ml compared with 6.16 log_{10} 1U/ml in those homozygous for the risk allele (p=1.21×10^{-10}). This is paradoxical since a higher pretreatment viral load has been associated with a poor response to subsequent IFNα treatment. It should be noted, however, that the presence or absence of the risk allele does not associate with the clinically relevant viral load cut-off (5.78log_{10} 1U/ml) that has been associated with response to IFNα therapy, and it is therefore likely that the effect of the protective allele on clinical outcome is independent of the effect of this allele on viral load.

IFNα and IFNλ ultimately exert their functions through the upregulation of ISGs. However, it has been repeatedly observed that a poor response to exogenous IFNα treatment is associated with a higher intrahepatic ISG expression before treatment. One plausible explanation is that, in this setting, the IFNα pathway (and thus ISG expression) is already maximally stimulated and is therefore unresponsive to further exogenous IFNα treatment. A recent study has shown that the protective allele identified in the GWAS (rs8099917) does not correlate with intrahepatic IFNα3 production. Technically there are reasons why this might be so; for example, the low levels of IFNα detected in general make correlations difficult and by the fact that, owing to sequence homology between IFNα3 and IFNλ2, quantification by real-time PCR does not distinguish between these cytokines. However, the protective allele does correlate with a lower expression of ISGs and, in those with the risk allele, lower levels of intrahepatic IFNα3 were associated with higher ISG (Mx1 IFI44 and IFIT1) expression. In fact, the assessment of ISGs in response to IFNs is not straightforward given that many hundreds of these are expressed in liver tissue that is composed of hepatocytes and also of immune and other cell types. For example, in the study by Honda and colleagues, 1559 genes were differentially expressed between individuals with and without the protective allele. Pathway analysis suggested that IFN action and apoptosis were upregulated in the liver of those with the risk allele, whereas immune cell (B, NK and dendritic cells) genes were expressed in those with the protective allele. This is supported by the observation that ISG expression is upregulated in Kupffer cells (liver macrophages) of IFNα responders compared with non-responders, whereas ISGs are upregulated in hepatocytes of non-responders compared with responders. In other words, the protective effect of the IFNλ3 allele may relate to the effects on or by ‘visiting’ cell populations rather than hepatocytes themselves.

In the setting of acute HCV infection, assuming the GWAS have correctly identified a genetic signal linked to IFNα, protective IFNα3 variants could mediate viral clearance through immune stimulation or direct antiviral effects through the stimulation of the ‘right’ ISGs. Exactly what these ISGs are and in which cells they are produced is not yet clear. In the setting of chronic infection where IFNα variants also appear to be associated with response to exogenous IFNα, the protective IFNα3 variant may well be linked to a complex intrahepatic ISG profile consisting of the ‘right’ ISGs produced by particular cell types (figure 5).

Undoubtedly, identifying exactly what the right ISGs are is a challenging but key question that will be addressed in months to come.

**CLINICAL STUDIES**

IFNα is potentially an attractive alternative to IFNα for the treatment of HCV infection. IFNα has been used to treat HCV since the discovery of the virus two decades ago. Over this time, important modifications to IFNα—such as the addition of polyethylene glycol (PEG) to increase drug half-life and the addition of ribavirin to treatment regimes—have been incorporated. Although in the coming years HCV protease and polymerase therapies will add to the anti-HCV drug armoury, the rapid emergence of HCV variants which are resistant to these new drugs means that IFNα will probably remain an essential component of treatment regimes. However, treatment with IFNα is associated with a very significant adverse event profile. Thrombocytopenia, neutropenia and psychiatric complications such as anxiety, depression and sleep disturbance are particularly troubling. An IFN with potent antiviral effects and a more favourable side effect profile would revolutionise the treatment of HCV. In vitro experiments have shown that IFNλ has a limited effect on CNS and haematopoietic cells. So, with its promising antiviral activity in the liver but restricted receptor distribution, IFNλ seems like the ideal candidate for development into a therapeutic agent.
The biology of IFN lambdas

- IFNλ is a type III IFN of which there are three types: IFNλ1, IFNλ2, IFNλ3 (IL29, IL28A, IL28B).
- Plasmacytoid dendritic cells are the main producers of IFNλ stimulated by viruses and viral or bacterial mimics.
- IFNλ has a restricted receptor distribution and therefore restricted targets.
- IFNλ has antiviral, antitumour and immunomodulatory effects.
- Upregulated hepatic ISGs pretreatment are associated with the IFNλ3 risk allele and with poor treatment outcome.
- The effect of IFNλ3 on HCV clinical outcome is likely to be a complex interplay between IFNλ, the virus itself, ISGs and immunomodulation.

Since the biological potential of IFNλs in general was recognised before the studies that implicated IFNλ3 in particular, clinical trials to date have not focused on IFNλ3 but rather on IFNλ1. Zymogenetics (in collaboration with Bristol-Myers Squibb) are assessing PEG-IFNλ1 in clinical studies which, while showing promising antiviral activity, have also uncovered a different but nevertheless significant side effect profile from that seen with IFNα. A phase I dose escalation study of PEG-IFNλ1 was presented in 2007 as an abstract (http://www.zymogenetics.com/products/documents/HEP_DART_PEG_IFN_12-07.pdf). Volunteers received a single subcutaneous injection of PEG-IFNλ1. The study was stopped after volunteers received 7.5 μg/kg, below the planned target maximum of 40 μg/kg, after four volunteers developed significantly elevated transaminases. As there was evidence of bioactivity at lower doses that were not associated with hepatotoxicity, and since peak serum concentrations at tolerated doses were higher than those shown to have antiviral effect in vitro, a phase I study in HCV-infected patients followed.

In this 4-week open-label trial, patients with genotype-1 HCV infection received PEG-IFNλ1 weekly or two-weekly. The study included both treatment-naïve patients (n=7) and patients with previous virological relapse with standard therapy (n=49). Despite the lower doses in this trial (0.5–3 μg/kg), six patients stopped or had treatment withheld due to elevated transaminase levels and four patients had raised lipase or amylase elevations which resolved after stopping PEG-IFNλ1. Although adverse effects were more common in the highest dose group, it is noteworthy that, at only 1.5 μg/kg, one patient developed severe hepatotoxicity with alanine transaminase levels of 667 IU/ml and bilirubin levels of 548.9 μmol/l. Furthermore, one patient developed idiopathic thrombocytopenic purpura and three patients developed antibodies to IFNλ1 during this short treatment course. Two patients previously treated with IFNα had cross-reactive antibodies to IFNλ1 at baseline (although only one of these was neutralising antibodies), suggesting that previous treatment with IFNα may limit IFNλ efficacy in some cases.

In keeping with the in vitro data showing a limited IFNλ1 receptor distribution, there was a noticeable decrease in IFNλ1-type side effects. Fatigue was the most common side effect (28.6%) followed by nausea and myalgia (12.5% and 10.7%, respectively). However, insomnia and influenza-like illness were only experienced in 5.4%, well below rates reported with IFNα and significant neutropenia did not occur. This trial also showed that IFNλ1 is capable of antiviral activity in vivo. In patients receiving a dose of ≥1.5 μg/kg/week, 23/24 patients with treatment relapse achieved a fall in viral load of ≥2log10 and four of these achieved a rapid virological response, defined as undetectable viraemia at 4 weeks. Interestingly, all eight African-American patients (a group known to respond poorly to IFNα treatment) in this study had a decline in viral load of >2log10 at the end of treatment. The association of virological response to PEG-IFNλ1 and IFNλ genotype has very recently been assessed in an ongoing phase II study (published in abstract form only) of PEG-IFNλ1 or PEG-IFNα with ribavirin combination therapy for 24–48 weeks, with a 2-week lead-in period of PEG-IFNλ1 or PEG-IFNα alone, in patients with genotypes 1–4 HCV infection. Interim results from patients receiving 120–240 μg PEG-IFNλ1, revealed a 71% viral response (VR) (>2log10 reduction in viral load) at week 4 in those with a favourable genotype compared with 25% VR in those carrying the risk allele. In this study, grade 2/3 hepatotoxicity was again observed (alanine transaminase or aspartate aminotransferase 2.5–20 times upper limited of normal) in 20% of patients on PEG-IFNλ1 which was, however, successfully managed with dose reduction.

IFNα may also in the future be considered both in the context of cancer therapy since this cytokine has been shown to suppress tumorigenesis in vitro and also as an immunomodulatory agent in the suppression of Th2-associated diseases such as allergy and atopy. IFNα may have a particular role in asthma since it suppresses IL-13 (known to be elevated in patients with asthma) and IFNα production in the bronchi of patients with asthma is associated with an increase in respiratory infections in this population.

The real utility of PEG-IFNλ1 in the treatment of HCV will become more apparent following the final results from the ongoing phase II trial described above which will assess both safety and

Clinical studies

- A phase I trial of PEG-IFNλ1 has shown promising antiviral activity in both treatment relapers and treatment-naïve patients with HCV.
- Hepatotoxicity has been associated with the clinical use of PEG-IFNλ1.
- Impaired IFNλ production may lead to increased susceptibility to viral infections.
- IFNλ3 provides the opportunity to apply pharmacogenomics to HCV treatment.
efficacy. Ultimately, new agents for HCV will need to be tolerable in the setting of pre-existing liver inflammation and poor hepatic reserve associated with liver cirrhosis.

CONCLUSION

The future is likely to bring IFNα3 and this exciting cytokine family further into the limelight, with head-to-head clinical trials between PEG-IFNα1 and PEG-IFNα2 underway for both HCV and HBV. Importantly, although genetic studies have now suggested that IFNα3 has a pivotal role in HCV clinical outcome, most work to date has been with IFNα1. IFNα3 may yet be developed as an alternative HCV treatment, particularly in those with the risk polymorphism, and genotyping for IFNα3-related SNPs may become part of a treatment decision algorithm. The differential effect of IFNα treatment on patients with and without the IL28B polymorphism is clearly an area worth further evaluation. Pharmacogenomic treatment approaches are one of the future challenges of medicine, and HCV provides the ideal opportunity to tailor potentially toxic therapies to individuals most likely to benefit. Whether work on this cytokine is applicable to genotypes other than 1 is still an open question, as is establishing the ideal therapeutic window for treatment with type III IFNs which have demonstrated hepatotoxicity in both healthy volunteers and patients with HCV infection. Furthermore, elucidating the pathway by which the IFNα3 polymorphism affects the response to acute infection and to IFN therapies remains an important future challenge. It is likely that defining the pattern of gene stimulation by IFNα in different cell types, as well as potential structural differences in IFNα3, will be critical in solving this puzzle. In particular, investigating the immunomodulatory effect of IFNα may well be key to unlocking the mechanism behind both its antiviral effect and its toxicities. Overall, the discovery of the link between the IFNα3 locus and HCV disease outcome has been a huge step forward for the field. However, while it has provided momentum for clinicians and basic scientists alike, the actual route ahead still needs careful charting. Nevertheless, while the destination is not yet clear, the journey itself will certainly be interesting.

Funding

CK is funded by the Oxford NIHR Biomedical Research Centre and Wellcome Trust UK, PK is funded by the Wellcome Trust UK and the Oxford NIHR Biomedical Research Centre, EB is funded by the Medical Research Council UK and the Oxford NIHR Biomedical Research Centre, PF is funded by the James Martin School for 21st Century and NIH V19A062630.

Competing interests

None.

Provenance and peer review

Commissioned; externally peer reviewed.

REFERENCES

1. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499–512.

2. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395–406.

3. Neumann-Haefelin C, Trimm J, Schmidt J, et al. The protective effect of HLA-B27 in hepatitis C virus infection requires presence of a genotype-specific immunodominant CD8+ T cell epitope. Hepatology 2010;51:54–62.

4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1226–33.

5. Mchutchison JG, Lawitz EJ, Shiffman ML, et al. Peg IFN α-2b or α-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–93.

6. Muir AJ, Bornstein JD, Killenberg PG. Peg IFN α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265–71.

7. Reddy KR, Houfmgale JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787–93.

8. De G, Fella J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.

9. Bauch A, Kutzik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–45.

10. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α2 and ribavirin therapy. Nat Genet 2009;41:1100–4.

11. Tanaka Y, Nishiha N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α (α) and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.

12. Labir D, Gilgenkrantz H. IL28B (interferon lambda3) gene polymorphisms and response to IFN-α alpha treatment in patients infected with hepatitis C virus. Med Sci 2010;26:225–6.

13. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821–7.

14. Montes-Canoe MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33–7.

15. McCarthy CJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2367–14.

16. Mosbruger TL, Duggal P, Goedert JJ, et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010;201:1371–80.

17. Rallon N, Nagie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus co-infected patients. AIDS 2010;24:723–9.

18. Thomas DL, Thioulouse M, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:789–90.

19. Cirilli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010;11:415–25.

20. Dickson SP, Wang K, Krantz I, et al. Rare variants create synthetic genome-wide associations. PLoS Biol 2010;8:e1000294.

21. Shepherd P, Kindsvogel W, Xu W, et al. IL-28B and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:53–8.

22. Kotenka NE, Gallagher G, Baun VV, et al. IFN-α mediates antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:59–77.

23. Pagliacci Net, Robek MD. Interferon-α in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res 2010;30:585–90.

24. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and III IFN α and interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796–805.

25. Megjugorac NJ, Gallagher GE, Gallagher G. IL-4 enhances IFN-α (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-18a. Blood 2010;115:4185–90.

26. Siren J, Pirhonen J, Julkunen I, et al. IFN-α regulates TRIF-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J Immunol 2005;174:1932–7.

27. Ank N, West H, Bartholdy C, et al. Lambda interferon IFN-λ, a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2008;80:4501–9.
28. Wolk K, Witte K, Sabat R. Interleukin-28 and interleukin-29: novel regulators of skin biology. J Interferon Cytokine Res 2010;30:617–28.
29. Mihno S, Frese M, Meier V, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004;84:1148–59.
30. Witte K, Gnutz G, Volk HD, et al. Despite IFN-α receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Gene Immun 2009;10:702–14.
31. Doyle SE, Schreckhise H, Khoo-Duong K, et al. Interleukin-29 uses a type I interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2008;48:986–906.
32. Mennechet FJD. Interferon–treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006;107:4417–23.
33. Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleukin (IL)-29 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004;279:32269–74.
34. Renaud JC. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003;3:667–76.
35. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1999;96:15623–9.
36. Rani MR, Foster GR, Leung S, et al. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 1996;271:22878–84.
37. Gadd HH, Delfgou C, Hammond DJ, et al. Interferon-λ is functionally an interferon but structurally related to the interferon-10 family. J Biol Chem 2009;284:20869–75.
38. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons α, β, and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2008;135:1597–98.
39. Dai J, Megjugorac NJ, Gallagher GE, et al. IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009;113:5829–38.
40. Jordan WD, Eskdale J, Srinivas S, et al. Human interferon lambda-1 (IFNa1) induces STAT1-dependent gene expression. Gene Immun 2007;8:254–61.
41. Srinivas S, Dai J, Eskdale J, et al. Interferon-λ1 (interleukin-29) preferentially down-regulates interferon-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008;125:492–502.
42. Morrow MP, Yang J, Pankhot P, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010;18:1714–23.
43. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008;83:1181–93.
44. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3951–4.
45. Muir AJ, Shiffman ML, Zamani A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822–32.
46. Pagliaccetti NE, Eduardo R, Kleinstein SH, et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008;283:30079–89.
47. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2002;137:975–82.
48. Hadziyannis SJ, Sette HJ, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
49. Honda M, Saki K, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;138:499–509.
50. Sarasin-Filipowicz M, Oakley EJ, Duong FHT, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034.
51. Chen L, Borzan I, Sun J, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010;138:1123–33.
52. Muir AJ, Lawitz E, Ghalib RH, et al. Pegylated interferon lambda (pegIFNa) phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naive HCV patients (genotypes 1, 2, 3 or 4): safety, viral response, and impact of IL-28B host genotype through week 12. Hepatology 2010;52:715A–16A.
53. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nat Med 2006;12:1023–6.